Sign up to save your podcasts
Or
Share EHA 2025: Toward Precision in AML Management
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
EHA 2025: Toward Precision in AML Management
A discussion between Dr. Daniel A. Pollyea and Dr. Stéphanie DésiletsDr. Pollyea and Dr. Désilets discuss key updates from EHA 2025 on acute myeloid leukemia (AML) treatments. They highlight promising results from trials on menin inhibitors like revumenib, ziftomenib, and bleximenib, especially in combinations with standard therapies.
They also review new venetoclax-based combinations and explore the potential of all-oral regimens to improve access for patients in remote areas. Lastly, they emphasize the value of real-world data to guide future AML treatment strategies.
Stéphanie Désilets, MD
Hemato-oncologist
CIUSSS Estrie-CHUS
Assistant professor at the Université de SherbrookeBio: Dr Désilets completed her specialisation in hemato-oncology at the Université de Sherbrooke. She did her fellowship in Lyon, France, at the Centre Leon Berard in autologous stem cell transplant and acute leukemias. She is currently practicing at the University Hospital in Sherbrooke (CHUS) with a focus on acute leukemias, lymphomas and autologous transplant.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Daniel A. Pollyea and Dr. Stéphanie DésiletsDr. Pollyea and Dr. Désilets discuss key updates from EHA 2025 on acute myeloid leukemia (AML) treatments. They highlight promising results from trials on menin inhibitors like revumenib, ziftomenib, and bleximenib, especially in combinations with standard therapies.
They also review new venetoclax-based combinations and explore the potential of all-oral regimens to improve access for patients in remote areas. Lastly, they emphasize the value of real-world data to guide future AML treatment strategies.
Stéphanie Désilets, MD
Hemato-oncologist
CIUSSS Estrie-CHUS
Assistant professor at the Université de SherbrookeBio: Dr Désilets completed her specialisation in hemato-oncology at the Université de Sherbrooke. She did her fellowship in Lyon, France, at the Centre Leon Berard in autologous stem cell transplant and acute leukemias. She is currently practicing at the University Hospital in Sherbrooke (CHUS) with a focus on acute leukemias, lymphomas and autologous transplant.